Eris Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
For the full year, revenue was INR 16,963.02 million compared to INR 13,731.37 million a year ago. Net income was INR 3,821.58 million compared to INR 4,061.13 million a year ago. Basic earnings per share from continuing operations was INR 28.1 compared to INR 29.89 a year ago. Diluted earnings per share from continuing operations was INR 28.07 compared to INR 29.88 a year ago.